Health Blueprint

Back to Longevity News

News summary

Copenhagen’s Biograil raises €20 million for oral drug delivery device designed as an alternative to injections

Source: EU-Startups Funding • Published: 04 Nov 2026, 10:23

Summarized by Masters of Longevity from EU-Startups Funding.

Copenhagen biotech secured €20 million to develop an oral drug delivery device.

Copenhagen’s Biograil raises €20 million for oral drug delivery device designed as an alternative to injections
Key Takeaways
  • Biograil raised €20 million to fund device development.
  • Investors Verve Ventures and Megatrend Invest backed the round.
  • Clinical efficacy in humans remains unproven and observational.
Read the full article at EU-Startups Funding ↗

Continue exploring

Recommended MoL Picks

MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.